Status:
Ready to upload
Record number:
2162
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
N/A. This Registry report covers a wide variety of tumor types in donors; no tumor transmissions are reported.
Time to detection:
N/A: This is a brief overview report of the Centre-Sud Transplant Organization area in Italy for the period January 2003-December 2010. During this time the Italian National Transplant Centre (CNT) initiated its Guidelines for the assessment of donor suitability and established a second opinion group. Of the 48 donors with neoplasia considered to be suitable for organ donation (out of a total of 377 potential donors with neoplasia), no tumor transmissions were recorded.
Alerting signals, symptoms, evidence of occurrence:
N/A
Demonstration of imputability or root cause:
N/A
Groups audience:
Keywords:
Suggest new keywords:
Malignancy
Registry Series
Deceased donor
Kidney transplant
Liver transplant
Heart transplant
Pancreas transplant
Lymphoma, type not specified
Lung cancer, other
Gallbladder cancer
Donor derived
Adrenal cancer, other or type not specified
Renal cell carcinoma
Renal oncocytoma (benign)
Meningioma
Prostate adenocarcinoma/carcinoma
Large bowel adenocarcinoma
Astrocytoma (WHO grade 2)
Thyroid cancer, other or type not specified
Oligodendroglioma (WHO grades 2-3)
Therapy not discussed
Vulvar carcinoma
Reference attachment:
Suggest references:
Fiaschetti P, Pretagostini R, Stabile D, Peritore D, Oliveti A, Gabbrielli F, Cenci S, Ricci A, Vespasiano F, Grigioni WF. The use of neoplastic donors to increase the donor pool. Transplant Proc. 2012 Sep;44(7):1848-50. doi: 10.1016/j.transproceed.2012.06.030. PMID: 22974853.
Note:
Uploaded MN 5/7/22
First review CLFF 5/25/22
Second review MN 1/26/23
Expert comments for publication:
The purpose of the study is to show positive results of applying the Guidelines of the Italian National Transplant Centre in regard to donors with neoplasia. No tumor transmissions were seen with organ transplants from 48 donors with neoplasia considered suitable by their criteria. No details are provided regarding tumor stage, degree of differnetiation, etc, so further conclusions are limited. The tumor types present in donors whose organs were utilized include: thyroid carcinoma, prostate carcinoma, renal cell carcinoma, oncocytoma, meningioma, dermatofibrosarcoma, verrucous vulvar carcinoma, colon adenocarcinoma, grade II astrocytoma, adrenal gland tumor, gastric GIST, and oligodendroglioma. The average followup was reported as 56.14 months.